Objective To prospectively examine the association between tea consumption and the risk of ischaemic heart disease (IHD).
Methods Prospective study using the China Kadoorie Biobank; participants from 10 areas across China were enrolled during 2004–2008 and followed up until 31 December 2013. After excluding participants with cancer, heart disease and stroke at baseline, the present study included 199 293 men and 288 082 women aged 30–79 years at baseline. Information on IHD incidence was collected through disease registries and the new national health insurance databases.
Results During a median follow-up of 7.2 years, we documented 24 665 (7.19 cases/1000 person-years) incident IHD cases and 3959 (1.13 cases/1000 person-years) major coronary events (MCEs). Tea consumption was associated with reduced risk of IHD and MCE. In the whole cohort, compared with participants who never consumed tea during the past 12 months, the multivariable-adjusted HRs and 95% CIs for less than daily and daily tea consumers were 0.97 (0.94 to 1.00) and 0.92 (0.88 to 0.95) for IHD, 0.92 (0.85 to 1.00) and 0.90 (0.82 to 0.99) for MCE. No linear trends in the HRs across the amount of tea were observed in daily consumers for IHD and MCE (PLinear >0.05). The inverse association between tea consumption and IHD was stronger in rural (PInteraction 0.006 for IHD, <0.001 for MCE), non-obese (PInteraction 0.012 for MCE) and non-diabetes participants (PInteraction 0.004 for IHD).
Conclusions In this large prospective study, daily tea consumption was associated with a reduced risk of IHD.
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Statistics from Altmetric.com
Tea is one of the most widely consumed beverages in the world, especially in China. Polyphenols, particularly flavonoids, which are of great abundance in tea, have been experimentally demonstrated to inhibit oxidation reactions caused by free radicals and prevent or delay atherosclerosis.1 ,2 Flavonoids have also been shown to have antithrombotic3 and anti-inflammatory properties,4 and may reverse endothelial dysfunction.5 Experimental evidence may collectively support a protective effect of tea consumption on ischaemic heart disease (IHD). Several previous prospective studies have related tea consumption with reduced risk of IHD,6–10 but several have not.11–16 These studies mostly had small sample sizes and were too low-powered to obtain precise effect estimates.
We therefore used data from the China Kadoorie Biobank (CKB) study,17 ,18 an ongoing cohort of 0.5 million adults, to prospectively examine the association of regular consumption of tea with the risk of IHD.
Subjects and methods
Details of the CKB study design and characteristics of the study participants have been described elsewhere.17 ,18 In brief, 512 891 participants aged 30–79 years were recruited between 2004 and 2008 from five urban and five rural regions of China.
A total of 10 964 men and 14 549 women was excluded from the present study because of a history of cancer (n=2577), heart disease (n=15 472) or stroke (n=8884) at baseline. Additionally, three participants who were recorded with an implausible censoring date for loss to follow-up were excluded. The final analyses included 199 293 men and 288 082 women.
Assessment of tea consumption
In the baseline questionnaire, all CKB participants were asked to report their frequency of tea consumption during the past 12 months. Five frequency categories were provided (never, only occasionally, only at certain seasons, monthly but less than weekly and at least once a week). Participants who consumed at least once a week were further asked about days consuming in a typical week (1–2 days/week, 3–5 days/week or almost every day), amount of tea (in 300 mL-sized cup) consumed in one consuming day, tea leaves (in gram) added each time, times of changing tea leaves in one consuming day, type of tea consumed most commonly (green tea, oolong tea, black tea or others) and age when they started tea consumption in most weeks. Participants were provided a pictorial guide to gauge the amount of tea in cup and tea leaves. The tea leaves added in one consuming day was calculated by multiplying amount added each time by times of changing tea leaves. To test the reproducibility of tea consumption frequency, 15 728 participants who completed the same question on frequency of tea consumption twice at a mean interval of 17 days were analysed. The weighted kappa coefficient for tea consumption was 0.77.
For the present analyses, all participants were grouped into three categories regarding their consumption frequency: never, less than daily and daily. Daily tea consumers were further categorised, according to rounded quartiles, as adding tea leaves 0.1–2.0, 2.1–3.0, 3.1–5.0 and >5.0 g/day; or consuming 1–2, 3–4, 5–6 and ≥7 cups of tea/day.
Assessment of covariates
Covariate information was obtained from baseline questionnaire, including sociodemographic characteristics (age, sex, education, occupation, household income and marital status), lifestyle behaviours (alcohol consumption, tobacco smoking, physical activity and intakes of red meat, fresh fruits and vegetables), personal medical history (hypertension, diabetes, chronic hepatitis or cirrhosis, peptic ulcer and gallstones or cholecystitis), women's menopausal status and family history of heart attack. The daily level of physical activity was calculated by multiplying the metabolic equivalent tasks (METs) value for a particular type of physical activity by hours spent on that activity per day and summing the MET-hours for all activities. Habitual dietary intake in the past year was assessed by a qualitative food frequency questionnaire. Prevalent hypertension was defined as measured systolic blood pressure ≥140 mm Hg, measured diastolic blood pressure ≥90 mm Hg, self-reported diagnosis of hypertension or self-reported use of antihypertensive medication at baseline. Prevalent diabetes was defined as measured fasting blood glucose ≥7.0 mmol/L, measured random blood glucose ≥11.1 mmol/L or self-reported diagnosis of diabetes. Trained staff undertook baseline measurements of bodyweight, height, waist circumference and blood pressure.
Assessment of outcome
The vital status of all CKB participants was obtained through linkage with local disease surveillance points system death registries19 and residential records. Information on IHD incidence was collected through linkage with established disease registries, electronic linkage with the new national health insurance (HI) claim databases.18 Participants who failed to be linked to local HI database were actively followed annually by staff to ascertain their status including hospital admission, death and moving out of the study area.
Trained staff blinded to baseline information coded all diagnoses and deaths using the International Classification of Diseases, Tenth Revision. The primary outcomes were (1) incident major coronary events (MCEs) including fatal IHD (I20–I25) and non-fatal myocardial infarction (I21–I23); and (2) a broader IHD outcome including incident fatal and non-fatal IHD (I20–I25), of which 80% coded as chronic IHD (I25). The outcome adjudication process of incident IHD cases has been started since 2014. The medical records of cases were retrieved, and the diagnosis was adjudicated centrally by qualified cardiovascular specialists blinded to study assay. By August 2015, of 12 923 incident IHD cases reported since baseline and whose medical records have been retrieved, the diagnosis was confirmed in 82.4% cases.
Person-years at risk were calculated for each participant from baseline (2004–2008) to the diagnosis of the outcome, death, loss to follow-up or 31 December 2013, whichever occurred first. By 31 December 2013, 2411 (0.5%) participants were lost to follow-up. Cox proportional hazards model was used to estimate the HR and 95% CI for the associations between tea consumption and outcomes with age as the underlying time scale, and stratified jointly by survey region and age at baseline in 5-year interval. The proportional hazards assumption for the Cox model was checked using Schoenfeld residuals and no violation was found.
Multivariate models were adjusted for established and potential risk factors for IHD: age, sex, level of education, marital status, alcohol consumption, smoking status, physical activity, body mass index (BMI), intake frequencies of red meat, fresh fruits and vegetables, prevalent hypertension and diabetes at baseline, menopausal status (for women only) and family history of heart attack. Tests for linear trend were only conducted in daily consumers by modelling the amount of tea consumption (in g/day or cup/day) as a continuous variable in separate models.
We examined the associations between tea consumption and outcomes according to the types of tea and years of tea consumption, all as compared with those who did not consume tea during the past 12 months. We also examined whether the associations of tea consumption with outcomes differed according to age, region, smoking status, alcohol consumption, the level of physical activity, BMI, hypertension at baseline and diabetes at baseline. In the subgroup analyses aforementioned, we combined four categories of daily tea consumption into one to ensure sufficient statistical power under the circumstance that no linear trend was observed across the amount of tea leaves added in the present analyses. The test for interaction was performed using likelihood ratio test, which involved comparing models with and without cross-product term between the baseline stratifying variable and tea consumption as an ordinal variable.
The statistical analyses were performed with Stata (V.13.1, Stata). All p values were two-sided, and statistical significance was defined as p<0.05.
Of 487 375 study participants, 128 280 (26.3%) reported consuming tea almost every day. Table 1 presents age-adjusted and region-adjusted baseline characteristics of the study participants according to tea consumption. Compared with participants who never consumed tea during the past 12 months, daily tea consumers who usually used more tea leaves were more likely to be younger, and urban residents, and more likely to smoke tobacco and drink alcohol. Green tea was the most common type of tea consumed in daily tea consumers.
During a median follow-up of 7.2 years, we documented 24 665 (7.19 cases/1000 person-years) incident IHD cases and 3959 (1.13 cases/1000 person-years) MCEs (including 2601 fatal IHD and 1358 non-fatal myocardial infarction). In the whole cohort, compared with participants who never consumed tea during the past 12 months, the multivariable-adjusted HRs (95% CIs) for IHD were 0.97 (0.94 to 1.00) for those who consumed tea less than daily, and 0.92 (0.87 to 0.97), 0.91 (0.85 to 0.98), 0.92 (0.87 to 0.98) and 0.91 (0.86 to 0.97) for those who consumed 0.1–2.0, 2.1–3.0, 3.1–5.0 and >5.0 g of tea leaves per day, respectively (table 2). The corresponding HRs (95% CIs) for MCE were 0.92 (0.85 to 1.00), 0.83 (0.74 to 0.95), 0.99 (0.85 to 1.15), 0.87 (0.75 to 1.00) and 0.97 (0.84 to 1.11). The HRs across four groups in daily consumers were statistically similar (p values for linear trend: 0.465 for IHD and 0.218 for MCE). After merging categories, the HRs (95% CIs) for daily consumers were 0.92 (0.88 to 0.95) for IHD and 0.90 (0.82 to 0.99) for MCE compared with participants who never consumed tea during the past 12 months. Tea consumption was consistently associated with reduced risks of IHD and MCE among both men and women (p values for interaction with sex: 0.158 for IHD and 0.659 for MCE). Sex-specific associations between tea consumption and both outcomes are presented in online supplementary table S1.
We also examined the associations of tea consumption measured in cups per day with the risk of IHD and MCE. The results were approximately similar (see online supplementary table S2). The associations of tea consumption with IHD and MCE did not change appreciably with additional adjustment for occupation and household income; or additional adjustment for histories of chronic hepatitis or cirrhosis, peptic ulcer and gallstone or cholecystitis; or adjustment for waist circumference instead of BMI; or exclusion of participants whose outcomes occurred during the first two years of follow-up; or exclusion of participants with prevalent diabetes at baseline; or exclusion of former tea consumers from never group (see online supplementary table S4).
We further performed subgroup analyses according to types of tea consumed most commonly and years of tea consumption in participants who consumed tea at least once a week. Similar associations of tea consumption with IHD and MCE were observed for both green tea consumers and non-green tea consumers. The inverse associations of daily tea consumption with both outcomes appeared to be stronger among participants who reported longer years of tea consumption (table 3).
We also analysed the associations of tea consumption with IHD and MCE according to potential baseline risk factors. The associations were similar across subgroups stratified according to age, smoking status, alcohol consumption, physical activity and prevalent hypertension (all p values for interaction >0.05). Significant differences in association with IHD and MCE across strata were observed for the region (p values for interaction: 0.006 for IHD and <0.001 for MCE), with stronger inverse associations among participants who resided in rural regions. Stronger inverse associations were also observed among participants with BMI <24 kg/m2 for MCE (p value for interaction: 0.012) and those without diabetes at baseline for IHD (p value for interaction: 0.004) (figure 1 and online supplementary table S3).
In this large prospective Chinese cohort, tea consumption was associated with a reduced risk of IHD. Compared with participants who never consumed tea during the past 12 months, those who consumed tea daily showed an 8% relative risk reduction in IHD and a 10% lower risk of MCE. The protective effect of tea consumption on IHD was stronger among participants who drank tea for more than three decades, who resided in a rural region, who had normal or lower BMI or who did not have diabetes at baseline.
Previous prospective studies have provided inconsistent results on the relationship between tea consumption and IHD.6–16 Two studies7 ,8 conducted in the Dutch population have shown that statistically significant protective effect of tea consumption, mainly black tea, on coronary heart disease (CHD) incidence were only observed for participants who drank tea >6 cups/day (HR 0.64, 95% CI0.46 to 0.90)7 or for those who drank >375 mL/day (0.57, 0.33 to 0.98).8 The Netherlands Cohort Study also observed an inverse association between an increment of 253 mL/day tea consumption and IHD mortality in men (HR 0.91, 95% CI 0.83 to 1.00).10 Findings from a Japanese population9 showed that the multivariable-adjusted HR (95% CI) for women drinking 1–6 cups/week, 1–2 cups/day, 3–5 cups/day and >6 cups/day were 0.34 (0.06 to 1.75), 0.28 (0.07 to 1.11), 0.39 (0.18 to 0.85) and 0.42 (0.15 to 0.92) for CHD mortality compared with non-drinkers of green tea. The inverse association was not observed among men. Another prospective study of Chinese6 reported that green tea consumption was associated with lower risk of CHD incidence (0.89, 0.81 to 0.98) compared with non-green tea consumers. No statistically significant association was found between tea consumption and IHD in other prospective studies conducted in the Japanese11 ,16 and Western population.12–15 In the present study, we observed that daily tea consumers were at a lower risk of IHD incidence than those who drank less than daily. However, the increasing amount of tea did not further reduce the risk of IHD, suggesting a possible threshold effect. Possible mechanisms might involve the bioaccessibility and bioavailability of polyphenols of tea,20 which needed to be verified by further studies.
Different types of tea differ in active ingredients, such as flavonoids, due to the difference in the degree of fermentation during the manufacturing process,20 suggesting potentially different cardiovascular protective effects. However, we found similar effects of green tea and non-green tea on reduced risk of IHD. Fewer participants in our population consumed other tea than green tea, which precluded further comparison of effects of black tea, oolong tea or other types of tea on IHD. Previous studies, either in the population mainly drinking black tea7–8 ,10 or in the population mainly drinking green tea,6 ,9 have observed the protective effect of tea consumption on IHD.
In the subgroup analysis by years of tea consumption, we found that the protective effect of tea consumption on the risk of IHD appeared to be stronger in participants who reported a longer history of consumption. Sesso et al12 have also indicated that long-term tea consumption may be necessary to confer health benefits. It has been suggested that there is no long-term storage of polyphenols in the body.21 Frequent exposure to physiological concentration of active ingredients over a long period of time may be necessary for beneficial effect.
Previous studies6–8 ,10 ,16 found that the association between tea consumption and the risk of IHD was consistent across subgroups defined by age, smoking status, BMI and the prevalence of hypertension and diabetes. However, in the present analyses, the protective effect of tea consumption on IHD was only observed in non-obese or non-diabetic participants. Polyphenols from tea, especially flavonoids, are the predominant contributor to the protective health effect.22 The mutual relationship between polyphenols and gut microbiota has received increasing attention in recent years.23 The gut microbiota transform polyphenols into their potentially more bioactive metabolites. The abundance and composition of gut microbiota have also been recently related to the obesity,24 diabetes25 and cardiovascular disease.26 Whether the altered gut microbiota among patients who are obese or diabetic may influence the assimilation and metabolism of polyphenols has yet to be further investigated. In addition, we observed that the protective effect of tea consumption on IHD was more pronounced in rural participants. It is possible that the flavonoids are easily available from other various food sources such as vegetables and fruits27 in the urban diet, and tea consumption added only modestly beneficial effect on IHD.
To our knowledge, this is by far the largest prospective study assessing the association between tea consumption and incident IHD. We have carefully controlled for established and potential risk factors for IHD. We measured tea consumption in gram of tea leaves added, which may be a better measure of tea consumption and at least partly reflect the intake amount of active ingredient.
A few limitations need to be considered. Tea consumption was self-reported, raising the possibility of misclassification. The questions on tea consumption have not yet validated directly. However, measurement errors in the prospective study design may be non-differential, and the association is more likely to be attenuated towards the null. Tea consumption may be correlated with other dietary habits and lifestyle behaviours. Residual confounding by other unmeasured or unknown factors was still possible. For example, coffee consumption may be a confounder but was not collected in this population at baseline. However, coffee is rarely consumed in the present population. Therefore, it is less likely that coffee consumption confounds the observed association substantially. Further, information was not available on tea brewing methods, which may influence the release of active ingredients of tea.28 Lack of detailed dietary information in this study limited our ability to examine whether population-specific dietary patterns modify the association between tea consumption and IHD and generalise the results to other population. Reverse causality could happen. Participants with diagnosed or subclinical chronic diseases may change consumption habits. However, we excluded participants with major diseases in our analyses. Moreover, the results did not change appreciably when we additionally adjusted for digestive system disorders or excluded participants who had IHD event during the first two years of follow-up.
In conclusion, data from this largest prospective cohort of Chinese adults showed that daily tea consumption was associated with a decreased risk of IHD incidence. Given the observational nature, this study alone could not establish a causal relationship. Further randomised studies may be needed to confirm the protective effect of tea consumption on IHD.
What is already known on this subject?
Previous prospective cohort studies observed inconsistent results on the role of tea in the prevention of ischaemic heart disease (IHD). In addition, evidence from the Netherlands and Japan suggested that the association might be dose–response relationship in daily tea consumers. However, these studies mostly had small sample sizes and were too low-powered to obtain precise effect estimates, leaving the relation between the tea consumption and IHD still less well established.
What might this study add?
Daily tea consumption was associated with a reduced risk of IHD in Chinese tea consumers. Intriguingly, daily tea consumers were at a lower risk of IHD incidence than those who drank less than daily, but the increasing amount of tea did not further reduce the risk.
The protective effect of tea consumption on IHD appeared to be stronger among participants who reported longer years of tea consumption, resided in rural regions, participants with body mass index <24 kg/m2, and those without diabetes at baseline.
In addition to measuring tea consumption by cups, which conducted by previous studies, we measured tea consumption in gram of tea leaves added, which may be a better measure of tea consumption and at least partly reflect the intake amount of active ingredient.
How might this impact on clinical practice?
The present study yields compelling evidence on understanding the role of tea in cardiovascular health and referring tea as a healthy beverage.
The chief acknowledgement is to the participants, the project staff and the China National Centre for Disease Control and Prevention (CDC) and its regional offices for assisting with the fieldwork. The authors thank Judith Mackay in Hong Kong; Yu Wang, Gonghuan Yang, Zhengfu Qiang, Lin Feng, Maigeng Zhou, Wenhua Zhao, and Yan Zhang in China CDC; Lingzhi Kong, Xiucheng Yu, and Kun Li in the Chinese Ministry of Health; and Sarah Clark, Martin Radley, Mike Hill, Hongchao Pan and Jill Boreham in the CTSU, Oxford, for assisting with the design, planning, organisation and conduct of the study.
Collaborators The members of steering committee and collaborative group are listed in the only online supplemental material (or Acknowledgements).
Contributors XL and CY contributed equally. LL, ZC and JC obtained funding. JL and LL conceived and designed the study. YG, ZB, LY, YC, XR, GJ and ZC acquired the data. XL, JS and CY analysed the data. XL and CY drafted the manuscript. JL and LL contributed to the interpretation of the results and critical revision of the manuscript for important intellectual content and approved the final version of the manuscript. All authors reviewed and approved the final abstract.
Funding This work was supported by grants (81390544, 81390541) from the National Natural Science Foundation of China. The CKB baseline survey and the first resurvey were supported by a grant from the Kadoorie Charitable Foundation in Hong Kong. The long-term follow-up is supported by grants from the UK Wellcome Trust (088158/Z/09/Z, 104085/Z/14/Z).
Competing interests None declared.
Patient consent Obtained.
Ethics approval The Ethical Review Committee of the Chinese Center for Disease Control and Prevention (Beijing, China) and the Oxford Tropical Research Ethics Committee, University of Oxford (UK).
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement See study website (www.ckbiobank.org) for access policy and procedures.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.